Advertisement

Topics

FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder

06:20 EDT 3 Jul 2017 | PharmPro

Ganaxolone is currently being evaluated in children with CDKL5 Disorder in a Phase 2 clinical trial. CDKL5 is a rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment.
Contributed Author: 
Marinus Pharmaceuticals, Inc.
Topics: 

Original Article: FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...